[Skip to Navigation]
Sign In
Comment & Response
April 16, 2020

The Role of Maintenance Therapy in Metastatic Colorectal Cancer

Author Affiliations
  • 1Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China
  • 2Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, China
JAMA Oncol. 2020;6(6):937. doi:10.1001/jamaoncol.2020.0580

To the Editor In a systematic review and network meta-analysis, Sonbol and colleagues1 found that maintenance therapy was significantly associated with progression-free survival (PFS) but not overall survival (OS) compared with observation following first-line induction therapy for metastatic colorectal cancer. Additionally, all 3 maintenance strategies (fluoropyrimidine, bevacizumab, and fluoropyrimidine plus bevacizumab) significantly improved PFS but not OS compared with observation, whereas fluoropyrimidine and fluoropyrimidine plus bevacizumab ranked higher than bevacizumab in PFS and OS. However, we have some concerns regarding the methodological aspects of this work.

Add or change institution